The American Journal of Managed Care

PET/MRI Detects Fibroblast Activity in Cardiomyopathy, Signals Prognosis

A new case-control study published in JAMA Cardiology demonstrates that molecular imaging using gallium-68–labeled fibroblast ...

FBLG: Advancing Fibroblast Therapy on Multiple Fronts

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Advancing Fibroblast Therapy on Multiple Fronts In the past month, ...
Hosted on MSN

FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…

On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
Nasdaq

FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment

HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
Business Insider

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...
Yahoo Finance

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE)-- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
Seeking Alpha

FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus

HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...